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Gestational diabetes (GDM) is caused by failure of islet b cells to meet the increased insulin requirements of
pregnancy. Recently, Prentice et al. (2014) discovered a 7-fold elevation of the furan fatty acid metabolite
3-carboxy-4-methyl-5-propyl-2-furanopropanoic acid (CMPF) in plasma of women with GDM and showed
that CMPF directly induces b cell dysfunction.Maternal metabolic adaptations to normal
pregnancy include the development of
both insulin resistance and a physiolog-
ical hyperlipidemia (Nolan, 2011). Gesta-
tional diabetes mellitus (GDM) develops
when there is a failure of islet b cells to
compensate for the insulin resistance
(Buchanan, 2001; Nolan, 2011). GDM is
also associated with exaggerated in-
creases in blood lipids raising the possi-
bility that lipotoxic b cell injury may have
a role in its pathogenesis (Koukkou
et al., 1996; Nolan, 2011). Although the
hyperglycemia of GDM usually resolves
postpartum, the condition is highly pre-
dictive of the subsequent development
of type 2 diabetes (T2D). Considering
that islet b cell failure to insulin resistance
is a necessary factor in the pathogenesis
of T2D, it is no surprise that GDM predicts
it so well (Prentki and Nolan, 2006). Pren-
tice et al. (2014) now identify the furan
fatty acid (FA) metabolite 3-carboxy-4-
methyl-5-propyl-2-furanopropanoic acid
(CMPF) as a mediator linking lipids to b
cell dysfunction in GDM and T2D.
Furan FAs are characterized by a furan
ring to which a 9-13 carbon FA, a short
3-5 carbon alkyl group and one or two
methyl groups are attached (Figure 1)
(Spiteller, 2005). They become incorpo-
rated into phospholipids, cholesterol
esters, and, to a lesser extent, triglycer-
ides (Spiteller, 2005). CMPF, a urinary
excreted dicarboxylic acid metabolite of
furan FAs (Figure 1) (Spiteller, 2005),
accumulates in chronic kidney disease
and is known to be a major uremic toxin,
possibly due to its pro-oxidant character-
istics (Miyamoto et al., 2012). It also
strongly binds to plasma proteins and
can interfere with drug binding. Urofuranswith pentyl alkyl moieties are excreted in
proportion to pentyl furan FAs in the diet
(mostly vegetables and fruit, but also pre-
sent in fish), whereas propyl alkyl moiety
urofurans, such as CMPF, appear in the
urine at much greater amounts than
would be expected from dietary propyl
furan FAs, such that the origin of CMPF
is less clear (Hannemann et al., 1989).
High-temperature cooking of polyunsatu-
rated fatty acids (PUFAs) such as linoleate
produces furanoid compounds that
potentially could give rise to higher levels
of CMPF (Berdeaux et al., 2012).
Using a metabolomics approach, Pren-
tice et al. (2014) discovered markedly
elevated CMPF levels in the plasma of
women with GDM. CMPF levels were
also shown to be 2- to 3-fold increased
in T2D subjects. Intraperitoneal adminis-
tration of CMPF to mice for 7 days mildly
increased basal insulin levels and abol-
ished glucose-stimulated insulin sec-
retion. CMPF had the same effect in vitro
on causing dysfunctional insulin secretion
in mouse and human islets, as well as in
MIN6 cells. In mouse islets, the CMPM-
induced b-cell dysfunction was associ-
ated with basal state mitochondrial
membrane hyperpolarization, increased
reactive oxygen species (ROS) produc-
tion and insulin degranulation (Prentice
et al., 2014). CMPF has been previously
shown to directly interact with superoxide
anion and peroxy radicals to produce
CMPF radicals (Miyamoto et al., 2012). It
has also been shown to cause renal
tubular damage via oxidative stress
(Miyamoto et al., 2012). In further support
of the author’s premise that CMPF’s detri-
mental islet effects are via oxidative
stress, Prentice et al. (2014) also showedCell Metabolismthat CMPF markedly increased the islet
expression of the antioxidant genes Cat
and Ucp-2, and that N-acetyl-cysteine
treatment of islets prevented CMPF-
induced dysfunction (Prentice et al.,
2014). Interestingly, CMPF-induced islet
b cell dysfunction could also be averted
by inhibiting its uptake into b cells via the
organic anion transporter 3 (OAT3,
Slc22a8) with probenecid or benzylpeni-
cillin (Prentice et al., 2014).Besides its
effect on mitochondrial function, it is
also important to consider that CMPF
may alter other key processes involved
in pregnancy-induced islet b cell com-
pensatory mechanisms. Considering its
avid serum protein binding properties,
it is certainly conceivable that CMPF
could bind to key proteins involved in
intracellular fatty acid metabolism. As
glycerolipid-fatty acid cycling in b cells
can prevent hyperpolarization of the mito-
chondrial membrane, an effect of CMPF
to inhibit this cycling could explain some
of the mitochondrial findings of the Pren-
tice experiments (Nolan et al., 2006;
Prentice et al., 2014).
Women with GDM don’t usually have
renal impairment, so why was a 7-fold
higher level of CMPF found by Prentice
et al. (2014) in the 24–28 week
fasting plasma of GDM compared to
matched normal glucose-tolerant preg-
nant women? These same GDM women
also had elevations in plasma free fatty
acid levels, particularly the PUFAs, which
is consistent with previous studies
showing elevated circulating lipid levels
in GDM; but none of the PUFAs were
elevated by anything like 7-fold. Synthesis
of furan FAs in the body from increased
availability of PUFAs could be occurring,19, April 1, 2014 ª2014 Elsevier Inc. 553
Figure 1. Chemical Structure of a Furan
Fatty Acid and Its Metabolism to the Bibasic
Urofuran CMPF
Furan fatty acids have a furan ring substituted with
a saturated fatty acid in one a position and either a
propyl or a pentyl alkyl group in the other a posi-
tion. Either both b positions are substituted with
methyl groups, or only the b position adjacent to
the fatty acid chain has amethyl group. Catabolism
to bibasic urofurans involves the degradation of the
a position long chain fatty acid to propianoic acid
and the conversion of the adjacent methyl group
to carboxylic acid. Shown here is a furan fatty
acid with a methyl group in both b positions and
a propyl alkyl group that is catabolized into CMPF.
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Previewsalthough there is no current evidence that
this occurs in humans. Plasma CMPF
levels were similarly elevated after preg-
nancy in GDM women, who had persist-
ing glucose intolerance (Prentice et al.,
2014), suggesting that altered lipid meta-
bolism during pregnancy (e.g., by the
placenta) was not a requirement for the554 Cell Metabolism 19, April 1, 2014 ª2014abnormal levels found in these same
women during pregnancy. Obesity did
not appear to be a factor linked to higher
CMPF in the T2D subjects studied; hyper-
glycemia, however, cannot be ruled out
as being able to affect CMPF levels. The
postpregnancy levels of CMPF in the
GDM women who had glucose tolerance
return to normal would have been of
interest, but this was not reported (Pren-
tice et al., 2014). The tested cohort of
GDM mothers may or may not be repre-
sentative of all GDM mothers, such that
the findings need to be corroborated in
other population groups. It will also be
very important to determine the relation-
ships between environmental factors, in
particular dietary factors, with CMPF
plasma levels in pregnant women. If, for
example, particular foods or methods of
food preparation (e.g., frying in PUFAs)
are found to be major determinants of
CMPF levels in pregnancy, dietary inter-
ventions that manage CMPF levels could
be trialed in the prevention and manage-
ment of GDM. Totally unknown is the
effect of a 7-fold elevation in maternal
blood CMPF on placental function and
the development of the fetus.
This novel finding that CMPF may
contribute to GDM and T2D pathogenesis
has the potential to be a major advance,
but it does need confirmation in further
patient groups. As its b cell entry via
OAT3 seems to be essential for CMPF’s
detrimental b cell effect, OAT3 couldElsevier Inc.be a new diabetes drug target. Safe
approaches to antioxidant therapy in
pregnancy also have therapeutic poten-
tial. However, the best outcome would
be the finding that simple dietary changes
can significantly lower plasma CMPF
levels and prevent and improve the
outcomes of both GDM and T2D.
REFERENCES
Berdeaux, O., Fontagne´, S., Se´mon, E., Velasco,
J., Se´be´dio, J.L., and Dobarganes, C. (2012).
Chem. Phys. Lipids 165, 338–347.
Buchanan, T.A. (2001). J. Clin. Endocrinol. Metab.
86, 989–993.
Hannemann, K., Puchta, V., Simon, E., Ziegler, H.,
Ziegler, G., and Spiteller, G. (1989). Lipids 24,
296–298.
Koukkou, E., Watts, G.F., and Lowy, C. (1996).
J. Clin. Pathol. 49, 634–637.
Miyamoto, Y., Iwao, Y., Mera, K., Watanabe, H.,
Kadowaki, D., Ishima, Y., Chuang, V.T., Sato, K.,
Otagiri, M., and Maruyama, T. (2012). Biochem.
Pharmacol. 84, 1207–1214.
Nolan, C.J. (2011). Best Pract. Res. Clin. Obstet.
Gynaecol. 25, 37–49.
Nolan, C.J., Madiraju, M.S., Delghingaro-Augusto,
V., Peyot, M.L., and Prentki, M. (2006). Diabetes 55
(Suppl 2 ), S16–S23.
Prentice, K.J., Luu, L., Allister, E.M., Liu, Y., Jun,
L.S., Sloop, K.W., Hardy, A.B., Li, W., Jia, W.,
Fantus, I.G., et al. (2014). Cell Metab. 19, this issue,
653–666.
Prentki, M., and Nolan, C.J. (2006). J. Clin. Invest.
116, 1802–1812.
Spiteller, G. (2005). Lipids 40, 755–771.
